GENALICE expands its NGS secondary data analysis suite with important functionality for better diagnosis of oncology patients

At the opening of the Annual Meeting of the American Society of Human Genetics, DTL partner GENALICE announced the release of a new version (V2.4.0) of its Next-Generation Sequencing (NGS) secondary data analysis suite, GENALICE MAP. The key component of this release is the Somatic Calling module, with impressive performance and best-in-class quality results. Somatic Calling is used for molecular diagnosis of oncology patients. It concerns a technology to distinct variants found in normal tissue from variants in a tumour sample, in order to identify tumour specific DNA mutations.

In a head-to-head comparison the GENALICE MAP Somatic Calling module outperforms the combination of four commonly used pipelines (MuTect, Strelka, FreeBayes, VarScan), by being 190 times faster and producing better results. None of the individual pipeline results came even close to the results of GENALICE MAP.

Hans Karten, CEO/CTO, explains: “With the addition of the Somatic Calling module, our NGS secondary analysis solution immediately becomes more relevant for clinical application. The exceptional validation results clearly show our added value in this field. This is an important step forward in realising the mission of our company to save lives and improve the quality of life of patients with complex DNA diseases, such as cancer.”